secwatch.observer — SEC 8-K summary
======================================

Issuer:     SpyGlass Pharma, Inc. (SGP)
CIK:        0001778922
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001778922-26-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SpyGlass Pharma reports FY2025 net loss $39.9M; positive Phase 1/2 data and $172.5M IPO
--------------------------------------------------------------------------------

- Net loss of $12.6M in Q4 2025 ($5.72/sh) and $39.9M for FY2025 ($17.98/sh).
- Cash $107.4M at Dec 2025; plus $172.5M IPO gross proceeds; runway through 2028.
- Positive 12-month Phase 1/2 data: 97% of patients off IOP-lowering drops; mean IOP reduction 34-42%.
- Phase 3 trials (SGP-005/SGP-006) enrolling; full enrollment expected 2027; BIM-DRS FIH trial in H2 2026.
- Appointed Jean-Frédéric Viret as CFO and Habib Dable to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1778922/000177892226000018/0001778922-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1778922/000177892226000018/sgp-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001778922-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer